https://cen.acs.org/pharmaceuticals/neuroscience/FDA-green-lights-lecanemab-treat/101/web/2023/01?utm_source=Newsletter&utm_medium=Newsletter&utm_campaign=CEN

Why are they charging so much for the drug? According to the developers:

“When it comes to the very high unmet need and the gravity of the disease, there has been recommendations for the use of a higher willingness-to-pay threshold. And definitely this is the case for Alzheimer’s disease.”

Because they can.